<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122925</url>
  </required_header>
  <id_info>
    <org_study_id>RAD-2017-25500</org_study_id>
    <nct_id>NCT03122925</nct_id>
  </id_info>
  <brief_title>TCA Cycle in the Dentate in Friedreich's Ataxia</brief_title>
  <official_title>Measurement of the TCA Cycle Rate in the Dentate Nucleus in Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE: To measure the tricarboxylic acid (TCA) cycle rate in the dentate nucleus in a&#xD;
      group of control subjects and subjects with Friedreich's Ataxia (FRDA).&#xD;
&#xD;
      HYPOTHESIS: The TCA cycle rate will be lower in FRDA subjects than in controls APPROACH: The&#xD;
      investigators will infuse carbon-13 (13C) labeled glucose and measure the rate of 13C label&#xD;
      incorporation from glucose to glutamate in the brain using in vivo magnetic resonance&#xD;
      spectroscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will measure the TCA cycle rate in the dentate nucleus in a group of FRDA&#xD;
      patients and in a group of age-matched healthy controls using 13C MRS in vivo together with&#xD;
      systemic i.v. infusion of 13C-labeled glucose.&#xD;
&#xD;
      The investigators aim to obtain adequate data in 16 subjects grouped as follows:&#xD;
&#xD;
        -  n=4 pilot subjects (healthy subjects) for testing and optimization of the experimental&#xD;
           setup.&#xD;
&#xD;
        -  n=6 healthy controls&#xD;
&#xD;
        -  n=6 FRDA patients&#xD;
&#xD;
      In other to reach this goal, the investigators plan to recruit up to 20 subjects, in case&#xD;
      some subjects withdraw before completion of the MR scan, or in case the measured data are not&#xD;
      adequate (e.g. technical problem with the scanner).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TCA cycle rate in the dentate nucleus</measure>
    <time_frame>Baseline</time_frame>
    <description>value between 0 to 2 micromol/g/min</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <description>Diagnosed for Friedreich's Ataxia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MR</intervention_name>
    <description>MR</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy controls Friedreich's Ataxia diagnosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  able to consent for themselves&#xD;
&#xD;
          -  considered healthy (controls) OR be diagnosed with FRDA.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All subjects:&#xD;
&#xD;
          -  Participants who cannot have an MRI, as determined by the CMRR safety screening form&#xD;
             (e.g. metal implant)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Clautrophobia&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
        Control subjects:&#xD;
&#xD;
        - Neurological disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Gilles Henry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMRR</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

